A pegylated derivative of α-galactosylceramide exhibits improved biological properties

Journal of Immunology

Volumn 179, Issue 4, 2007, Pages 2065-2073

  Ebensen, Thomas ^a   Link, Claudia ^a   Riese, Peggy ^a   Schulze, Kai ^a   Morr, Michael ^a   Guzmán, Carlos A ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; BETA GALACTOSIDASE; CD1D ANTIGEN; IMMUNOLOGICAL ADJUVANT; ALPHA-GALACTOSYLCERAMIDE; ANTIGEN; GALACTOSYLCERAMIDE; IMMUNOGLOBULIN A; IMMUNOLOGIC FACTOR; MACROGOL DERIVATIVE; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL ACTIVATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG CONJUGATION; FEMALE; HUMORAL IMMUNITY; IMMUNOMODULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPLEEN CELL; TH2 CELL; ANIMAL; ANTIBODY SPECIFICITY; CELL LINE; CHEMISTRY; CHRONIC DISEASE; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFECTION; INFLAMMATION; INTRANASAL DRUG ADMINISTRATION; MUCOSA; MUCOSAL IMMUNITY; NEOPLASM; SOLUBILITY; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS; BETA-GALACTOSIDASE; CELL LINE; CHRONIC DISEASE; DENDRITIC CELLS; GALACTOSYLCERAMIDES; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOLOGIC FACTORS; INFECTION; INFLAMMATION; MICE; MUCOUS MEMBRANE; NEOPLASMS; OLIGONUCLEOTIDES; POLYETHYLENE GLYCOLS; SOLUBILITY; SPLEEN;

EID: 34848874475     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.4.2065     Document Type: Article

References (55)

1. Yamauchi, A., S. Y. Dai, R. Nakagawa, Y. Kashio, H. Abe, S. Katoh, K. Kontani, and M. Hirashima. 2005. [Galectin-9 induces maturation of human monocyte-derived dendritic cells]. Nihon Rinsho Meneki Gakkai Kaishi 28: 381-388.
2. Cheroutre, H., and L. Madakamutil. 2005. Mucosal effector memory T cells: the other side of the coin. Cell Mol. Life Sci. 62: 2853-2866.
3. + T cells. Proc. Natl. Acad. Sci. USA 101: 6116-6121.
4. Schlede, E., T. Maurer, M. Potokar, W. M. Schmidt, K. H. Schulz, R. Roll, and D. Kayser. 1989. A differentiated approach to testing skin sensitization: proposal for a new test guideline skin sensitization. Arch. Toxicol. 63: 81-84.
5. Nagler-Anderson, C. 2001. Man the barrier: strategic defences in the intestinal mucosa. Nat. Rev. Immunol. 1: 59-67.
6. Fooks, A. R. 2000. Development of oral vaccines for human use. Curr. Opin. Mol. Ther. 2: 80-86.
7. Cavallo, F., A. Astolfi, M. Iezzi, F. Cordero, P. L. Lollini, G. Forni, and R. Calogero. 2005. An integrated approach of immunogenomics and bioinformatics to identify new tumor associated antigens (TAA) for mammary cancer immunological prevention. BMC Bioinformatics 6(Suppl. 4): S7.
8. Guy, B., and N. Burdin. 2005. New adjuvants for parenteral and mucosal vaccines. Therapie 60: 235-241.
9. Burdin, N., B. Guy, and P. Moingeon. 2004. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 18: 79-93.
10. Di Guilmi, A. M., and A. Dessen. 2002. New approaches towards the identification of antibiotic and vaccine targets in Streptococcus pneumoniae. EMBO Rep. 3: 728-734.
11. Teicher, B. A. 2000. Molecular targets and cancer therapeutics: discovery, development and clinical validation. Drug Resist. Updat. 3: 67-73.
12. Lizotte-Waniewski, M., W. Tawe, D. B. Guiliano, W. Lu, J. Liu, S. A. Williams, and S. Lustigman. 2000. Identification of potential vaccine and drug target candidates by expressed sequence tag analysis and immunoscreening of Onchocerca volvulus larval cDNA libraries. Infect. Immun. 68: 3491-3501.
13. Kobayashi, E., K. Motoki, T. Uchida, H. Fukushima, and Y. Koezuka. 1995. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7: 529-534.
14. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science 278: 1626-1629.
15. Sekine, K., H. Fujii, F. Abe, and K. Nishikawa. 2001. Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines. Int. J. Cancer 94: 485-491.
16. Sharif, S., G. A. Arreaza, P. Zucker, and T. L. Delovitch. 2002. Regulatory natural killer T cells protect against spontaneous and recurrent type 1 diabetes. Ann. NY Acad. Sci. 958: 77-88.
17. Sharif, S., G. A. Arreaza, P. Zucker, Q. S. Mi, J. Sondhi, O. V. Naidenko, M. Kronenberg, Y. Koezuka, T. L. Delovitch, J. M. Gombert, et al. 2001. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat. Med. 7: 1057-1062.
18. Singh, A. K., M. T. Wilson, S. Hong, D. Olivares-Villagomez, C. Du, A. K. Stanic, S. Joyce, S. Sriram, Y. Koezuka, and L. Van Kaer. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1801-1811.
19. Hong, S., M. T. Wilson, I. Serizawa, L. Wu, N. Singh, O. V. Naidenko, T. Miura, T. Haba, D. C. Scherer, J. Wei, et al. 2001. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7: 1052-1056.
20. Teige, A., I. Teige, S. Lavasani, R. Bockermann, E. Mondoc, R. Holmdahl, and S. Issazadeh-Navikas. 2004. CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis. J. Immunol. 172: 186-194.
21. van Dommelen, S. L., H. A. Tabarias, M. J. Smyth, and M. A. Degli-Esposti. 2003. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J. Virol. 77: 1877-1884.
22. Furlan, R., A. Bergami, D. Cantarella, E. Brambilla, M. Taniguchi, P. Dellabona, G. Casorati, and G. Martino. 2003. Activation of invariant NKT cells by αGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-γ. Eur. J. Immunol. 33: 1830-1838.
23. Gonzalez-Aseguinolaza, G., L. Van Kaer, C. C. Bergmann, J. M. Wilson, J. Schmieg, M. Kronenberg, T. Nakayama, M. Taniguchi, Y. Koezuka, and M. Tsuji. 2002. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195: 617-624.
24. Gonzalez-Aseguinolaza, G., C. de Oliveira, M. Tomaska, S. Hong, O. Bruna-Romero, T. Nakayama, M. Taniguchi, A. Bendelac, L. Van Kaer, Y. Koezuka, and M. Tsuji. 2000. α-Galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria. Proc. Natl. Acad. Sci. USA 97: 8461-8466.
25. Shin-ichiro, F., K. Shimizu, C. Smith, L. Bonifaz, and R. M. Steinman. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198: 267-279.
26. Kopecky, E. M., S. Greinstetter, I. Pabinger, A. Buchacher, J. Romisch, and A. Jungbauer. 2006. Effect of oriented or random PEGylation on bioactivity of a factor VIII inhibitor blocking peptide. Biotechnol. Bioeng. 93: 647-655.
27. Frokjaer, S., and D. E. Otzen. 2005. Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4: 298-306.
28. Deckert, P. M., A. Jungbluth, N. Montalto, M. A. Clark, R. D. Finn, C. Williams, Jr., E. C. Richards, K. S. Panageas, L. J. Old, and S. Welt. 2000. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts. Int. J. Cancer 87: 382-390.
29. Bradley, M. P., L. A. Hinds, and P. H. Bird. 1997. A bait-delivered immunocontraceptive vaccine for the European red fox (Vulpes vulpes) by the year 2002? Reprod. Fertil. Dev. 9: 111-116.
30. Hessel, E. M., M. Chu, J. O. Lizcano, B. Chang, N. Herman, S. A. Kell, M. Wills-Karp, and R. L. Coffman. 2005. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J. Exp. Med. 202: 1563-1573.
31. Molineux, G. 2003. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 23: 3S-8S.
32. Guiotto, A., M. Pozzobon, M. Canevari, R. Manganelli, M. Scarin, and F. M. Veronese. 2003. PEGylation of the antimicrobial peptide nisin A: problems and perspectives. Farmaco 58: 45-50.
33. DeSantis, G., and J. B. Jones. 1999. Chemical modification of enzymes for enhanced functionality. Curr. Opin. Biotechnol. 10: 324-330.
34. Pomroy, N. C., and C. M. Deber. 1998. Solubilization of hydrophobic peptides by reversible cysteine PEGylation. Biochem. Biophys. Res. Commun. 245: 618-621.
35. Katre, N. V. 1990. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol. 144: 209-213.
36. Zhou, S., X. Liao, X. Li, X. Deng, and H. Li. 2003. Poly-D,L- lactide-co-poly-(ethylene glycol) microspheres as potential vaccine delivery systems. J. Control Release 86: 195-205.
37. Ortaldo, J. R., H. A. Young, R. T. Winkler-Pickett, E. W. Bere, Jr., W. J. Murphy, and R. H. Wiltrout. 2004. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 172: 943-953.
38. De Vendittis, E., G. Palumbo, G. Parlato, and V. Bocchini. 1981. A fluorimetric method for the estimation of the critical micelle concentration of surfactants. Anal. Biochem. 115: 278-286.
39. Nerenberg, S. T., C. Ganger, and L. DeMarco. 1971. Rapid fluorescent "staining" of nondenatured protein bands in agar and polyacrylamide gels. Anal. Biochem. 43: 564-574.
40. Ebensen, T., S. Paukner, C. Link, P. Kudela, C. de Domenico, W. Lubitz, and C. A. Guzman. 2004. Bacterial ghosts are an efficient delivery system for DNA vaccines. J. Immunol. 172: 6858-6865.
41. Borsutzky, S., V. Fiorelli, T. Ebensen, A. Tripiciano, F. Rharbaoui, A. Scoglio, C. Link, F. Nappi, M. Morr, S. Butto, et al. 2003. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur. J. Immunol. 33: 1548-1556.
42. Giaccone, G., C. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. von Blomberg, R. Scheper, H. van der Vliet, A. van den Eertwegh, et al. 2002. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8: 3702-3709.
43. Borsutzky, S., T. Ebensen, C. Link, P. D. Becker, V. Fiorelli, A. Cafaro, B. Ensoli, and C. A. Guzman. 2006. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 24: 2049-2056.
44. Godfrey, D. I., and M. Kronenberg. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114: 1379-1388.
45. Ko, S. Y., H. J. Ko, W. S. Chang, S. H. Park, M. N. Kweon, and C. Y. Kang. 2005. α-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175: 3309-3317.
46. Ishikawa, A., S. Motohashi, E. Ishikawa, H. Fuchida, K. Higashino, M. Otsuji, T. Iizasa, T. Nakayama, M. Taniguchi, and T. Fujisawa. 2005. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11: 1910-1917.
47. Chang, D. H., K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201: 1503-1517.
48. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383-389.
49. Banchereau, J., C. Bidaud, A. C. Fluckiger, L. Galibert, P. Garrone, F. Malisan, and D. Pandrau. 1993. Effects of interleukin 4 on human B-cell growth and differentiation. Res. Immunol. 144: 601-605.
50. Gemmell, E., C. L. Carter, P. S. Bird, and G. J. Seymour. 2002. Genetic dependence of the specific T-cell cytokine response to Porphyromonas gingivalis in mice. J. Periodontol. 73: 591-596.
51. Gemmell, E., K. E. Drysdale, and G. J. Seymour. 2006. Gene expression in splenic CD4 and CD8 cells from BALB/c mice immunized with Porphyromonas gingivalis. J. Periodontol. 77: 622-633.
52. Gemmell, E., C. Sernia, D. A. Grieco, P. S. Bird, C. J. Allen, and G. J. Seymour. 2001. Genetic variation in the recognition of Porphyromonas gingivalis antigens in mice. Oral Microbiol. Immunol. 16: 129-135.
53. Gemmell, E., T. A. Winning, D. A. Grieco, P. S. Bird, and G. J. Seymour. 2000. The influence of genetic variation on the splenic T cell cytokine and specific serum antibody responses to Porphyromonas gingivalis in mice. J. Periodontol. 71: 1130-1138.
54. Urry, Z., E. Xystrakis, and C. M. Hawrylowicz. 2006. Interleukin-10- secreting regulatory T cells in allergy and asthma. Curr. Allergy Asthma Rep. 6: 363-371.
55. Zhou, X., P. Schmidtke, F. Zepp, and C. U. Meyer. 2005. Boosting interleukin-10 production: therapeutic effects and mechanisms. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 465-475.